Currently, only a subset of patients with chronic myeloid leukemia (CML) pursuing treatment-free remission (TFR) enjoy success. At the 64th ASH Ann......READ MORE
Although great progress has been made in the treatment of chronic phase chronic myeloid leukemia (CML), many patients still experience intolerance ......READ MORE
conference reporter by Carlos M. de Castro III, MD
Data from several studies presented at the 64th ASH Annual Meeting and Exposition highlight the promise of proximal complement inhibition in the tr......READ MORE
conference reporter by Carlos M. de Castro III, MD
Researchers at the 64th ASH Annual Meeting and Exposition presented data from several studies evaluating the treatment of paroxysmal nocturnal hemo......READ MORE
At the 64th ASH Annual Meeting and Exposition, emerging data underscored the importance of tyrosine kinase inhibitor (TKI) tolerability and dose op......READ MORE
The treatment of chronic phase chronic myeloid leukemia (CML) is evolving in response to newer data on BCR::ABL1 tyrosine kinase inhibitors (TKIs).......READ MORE